We are snap-polling US and European oncologists to get a better understanding.
New Phase III data show that AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a 72% reduction in the risk of disease progression or death compared to Kadcyla when used to treat patients with HER2-positve unresectable and/or metastatic breast cancer previously treated with Herceptin (trastuzumab).
More on the results here
Enhertu is already approved as a third-line therapy and Daiichi Sankyo and AstraZeneca now plan to file it with regulators as a second-line treatment option.
Our snap-poll is asking oncologists to rate the efficacy and safety profile of Enhertu, how they anticipate using in the future versus Kadcyla and whether these data will drive an overall increase in the use of antibody drug conjugate (ADC) therapy for the treatment of HER2-positive breast cancer.
Results and analysis will be published as soon as possible for FirstWord Pharma PLUS subscribers and can be purchased by non-FirstWord Pharma PLUS subscribers. To be notified when they become available, click here.
To read more Physician Views articles, click here.